Catalyst Pharmaceuticals, Inc. (CPRX)

NASDAQ • Healthcare

$31.49

+$0 (+0.0%)

Market open

Last close at July 21, 2026 at 20:00 UTC

Open$31.49

Previous Close$31.49

Day Range$31.49 - $31.49

Avg. Volume (3M)0

Market Cap$3.8B

P/E Ratio17.5

52 Week Range

$20.66$32.56

Metrics Over Time

Where the Money Goes

Q1 2026

Revenueeverything earned$149.3M100%

Gross Profitminus cost of goods$125.2M84%

Operating Incomeminus R&D and overhead$73.2M49%

Net Incomeminus taxes and the rest$63.7M43%

In plain terms: out of every $100 in revenue, Catalyst Pharmaceuticals, Inc. keeps $43 as net profit.

Fundamentals & Financials

Revenue (TTM)

$596.9M

Net Income (TTM)

$221.3M

EPS (TTM)

$1.8

ROA (TTM)

19.29%

Current Ratio

7.1

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-11.3%Q2 2025$0.47

-25.9%Q3 2025$0.43

-15.7%Q4 2025$0.43

0.0%Q1 2026$0.42

-18.8%Q2 2026$0.52

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q2 2026

Miss -18.8%

Catalyst Pharmaceuticals’ adjusted EPS of $0.52 trailed the $0.64 estimate by 18.8% and rose 10.6% from $0.47 a year ago, while revenue of $149.4 million was in line with the $149.5 million consensus, -0.1%, in the fiscal first quarter of 2026 reported on May 11. Revenue increased 5.6% to about $149.4 million from $141.4 million a year earlier, with gross margin near 83.8% and operating margin around 49.0% as the company kept profitability high. Net income climbed 12.3% to about $63.7 million from $56.7 million a year ago, operating cash flow came in at about $59.6 million, and Catalyst repurchased roughly $14.6 million of stock. For the next period, consensus calls for adjusted EPS of $0.48 on revenue of $155.8 million.

View full earnings history

About Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a commercial-stage biotechnology company that discovers, develops, and markets therapies for rare, severe, and chronic neuromuscular and neurological disorders in the United States. The company generated $589.0 million in revenue in FY2025 from a business centered on approved LEMS treatments and follow-on development.

Name

Catalyst Pharmaceuticals, Inc.

CEO

Richard John Daly

Website

www.catalystpharma.com

Industry

Healthcare

Year Founded

2002

Employees

182

Today's Snapshot

AI-generated

CPRX closed flat at 31.49, while its sector was weaker. At the close, CPRX was within 3.3% of its 52-week high of 32.56.

vs S&P 500 Today

Outperforming Market

+0.52%

Updated: October 23, 2026 at 20:07 UTC

Technical Indicators

5 Buy1 Neutral2 Sell

CPRX displays a strong trending character, underscored by a very high ADX and price comfortably above its 50- and 200-day averages, which indicates broad moving-average support. Short-term momentum metrics are stretched—RSI and stochastic show overbought readings—while MACD is only modestly positive and momentum is flat, and volatility is very low with tight Bollinger bands and a minimal ATR. On-balance volume is robust, signaling accumulation. Technical takeaway: Strong Buy — trend strength and notable volume favor the prevailing uptrend despite short-term overbought readings.

All signals